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  We  evaluated  the  pharmacokinetics  of  ciprofloxacin  in 
serum (n = 6) and urine (n = 4) in goats following a single 
intravenous administration of 4 mg/kg body weight. The 
serum  concentration-time  curves  of  ciprofloxacin  were 
best fitted by a two-compartment open model. The drug 
was detected in goat serum up to 12 h. The elimination 
rate constant (β) and elimination half-life (t1/2β) were 0.446 
±  0.04 h
-1 and 1.630 ±  0.17 h, respectively. The apparent 
volume of distribution at steady state (Vdss) was 2.012 ± 
0.37 l/kg and the total body clearance (ClB) was 16.27 ± 
1.87  ml/min/kg.  Urinary  recovery  of  ciprofloxacin  was 
29.70% ±  10.34% of the administered dose within 36 h 
post administration.  In  vitro  serum protein binding  was 
41% ±  13.10%. Thus, a single daily intravenous dose of 4 
mg/kg  is  sufficient  to  maintain  effective  levels  in  serum 
and  for  36  h  in  urine,  allowing  treatment  of  systemic, 
Gram-negative  bacterial  infections  and  urinary  tract 
infections by most pathogens. 
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Introduction 
  Ciprofloxacin is a fluoroquinolone derivative in veterinary 
medicine with outstanding antibacterial activity primarily 
against Gram-negative pathogens, but also Gram-positive 
bacteria and some Chlamydia,  Mycoplasma, and many 
Mycobacterium species [12,23,24]. The pharmacokinetics 
of ciprofloxacin has been investigated in dogs, rats and 
monkeys, rabbits, ponies, goats, cow calves, and buffalo 
calves [4,8,29,30,33,34,37]. Because of the lack of 
sufficient pharmacokinetic studies in goats and potential 
species differences, we evaluated the pharmacokinetics of 
ciprofloxacin after intravenous administration in goats.
Materials and Methods
Experimental animals
  Ten clinically healthy goats (15-20 kg) were procured from 
a local breeding farm in Jammu, India, and housed in a 
well-ventilated house. All de-wormed animals were housed 
in hygienic departmental shed for 20 d prior to experiments 
for acclimatization, and allowed free access to pasture, ad 
libitum water, and received once daily concentrated feed 
ration. No treatments were performed for two weeks before 
study initiation. One day prior to the experiment, the goats 
underwent thorough physical and clinical examinations.
Experimental design
  The study was performed in two phases. In phase I, six 
goats were used for evaluating the disposition kinetics of 
ciprofloxacin. A single intravenous dose of 4 mg/kg body 
weight of ciprofloxacin hydrochloride monohydrate in 
sterile distilled water (Cadilla Labs Private, India) was 
administered into the jugular vein of the six goats. Blood 
samples of 6-7 ml were obtained directly from the jugular 
vein using disposable needles. The blood samples were 
collected in un-heparinized test tubes just prior to and at 
2.5, 5, 10, 20, 30, 45, 60 and 90 min and 2, 3, 4, 6, 9 and 12 
h after drug administration. Blood samples were allowed to 
clot at ambient temperature for the collection of serum. The 
separated serum was then centrifuged for 15 min at 3,000 
g to obtain clear supernatant fluid and stored at -20
oC until 
analysis, usually within 2-3 days. 
  In phase II, the urinary excretion of ciprofloxacin was 
investigated in four goats. The dose and route of 
administration were the same as in phase I. The animals 
were placed into metabolic stalls prior to start of the 
experiment and total urine was collected. The urine 
samples were collected at 0-3, 3-6, 6-9, 9-12, 12-24, 24-36, 242    R. Raina et al.
Table 1. Pharmacokinetic parameters of ciprofloxacin in goat (n
= 6) following a single intravenous administration with 4 mg/kg 
body weight
Parameters Units Mean ± SD
  Compartmental analysis
C
o
p μg/ml   4.470 ± 0.33
α h
−1   8.224 ± 1.99
β h
−1   0.446 ± 0.04
K12 h
−1   3.826 ± 0.89
K21 h
−1   3.814 ± 1.22
K12/ K21 Ratio   1.162 ± 0.21
Kel h
−1   0.926 ± 0.13
t1/2α h   0.108 ± 0.03
t1/2β h   1.630 ± 0.17
Vc l/kg   0.918 ± 0.06
ClB ml/min/kg   16.27 ± 1.87
  Non-compartmental analysis
AUC0→12 μg.h/ml   5.580 ± 0.93
AUC0→∞ μg.h/ml   5.750 ± 0.92
MRT h   2.510 ± 0.18
AUMC μg.h
2/ml 14.310 ± 2.27
VdSS l/kg   2.012 ± 0.37
r
2 −   0.982 ± 0.009
C
o
p-Serum drug concentration at t=0; α and β-hybrid rate constants 
represent the slopes of distribution and elimination phases, respectively;
t1/2α-distribution half-lives; t1/2β-elimination half- lives; kel-first 
order elimination rate constant, Vc-volume of distribution from 
central compartment; VdSS-volume of distribution at steady-state; 
K12-rate constant of transfer of drug from central compartment into
the tissue compartment; K21-rate constant of transfer of drug from 
tissue compartment into the central compartment; AUC0→12-Area 
under the serum concentration vs. time curve from 0 to 12 h; AUC0→
∞-Area under the serum concentration vs. time curve from 0 to ∞; 
AUMC area under the first moment curve; MRT-mean residence 
time; ClB-total body clearance; r
2-Correlation coefficient fit curve of 
serum concentration vs time profile.
Fig. 1. Semi-logarithmic graph depicting the serum concentration-
time profile of ciprofloxacin in goat following single intravenous
dose of 4 mg/kg body weight (n = 6).
and 36-48 h after drug administration. The whole volume 
of urine was measured and 10 ml urine samples were taken 
for analysis. 
  Ciprofloxacin concentrations in serum and urine were 
determined using the agar well diffusion assay [5], using E. 
coli ATCC-25922 as test organisms grown on Mueller 
Hinton agar. This method correlates well with HPLC 
studies [16]. Standard concentrations (0.015 to 4 mg/ml) 
were prepared in pooled untreated goat serum and urine, 
and showed a mean correlation coefficient (r) ＞ 0.99% for 
both serum and urine. The serum concentration time 
profile showed a correlation coefficient (r
2) value of 0.982 
± 0.009. The intra-assay and inter-assay precision 
variability were ＜10% for standard concentrations in both 
serum and urine. The lower limit of quantification of the 
ciprofloxacin assay was 0.015 μg/ml.
  The extent of protein binding was determined in vitro 
using an equilibrium dialyzing technique as described by 
Kunin [18]. To estimate the protein binding of 
ciprofloxacin, the drug was dissolved in 0.06 M phosphate 
buffer (pH 7.0) and antibiotic-free healthy goat serum at 
0.5, 0.75, 1.0, 1.5, and 2.0 μg/ml. The differences in the 
diameters of the inhibition zone between the solution of the 
drugs in the buffer and serum were calculated.
Pharmacokinetics analysis
  The compartment pharmacokinetics of serum concentration- 
time curves after single intravenous injection were 
analyzed for each goat by Top-Fit v. 2.0 [13]. The best-fit 
model was selected based on Akaike’s Information 
Criterion and the Schwartz test [31,40]. Model-dependent 
pharmacokinetic parameters were obtained as described 
by Baggot [3] and Gibaldi and Perrier [11]. The two 
compartment open model was the best fit for intravenous 
injection of ciprofloxacin. Statistical moments were also 
used to compute the non-compartmental pharmacokinetic 
analysis [11,40]. The non-compartment model was used to 
determine the area under concentration-time curve (AUC), 
and area under the first moment curve (AUMC), using the 
linear trapezoidal rule with extrapolation to time infinity. 
Mean residence time (MRT) and systemic clearance (ClB) 
were calculated as MRT = AUMC/AUC and ClB = 
Dose/AUC, respectively. The apparent volumes of 
distribution at steady state were calculated as VdSS = (Dose 
× AUMC)/AUC
2.
Results
    Mean serum ciprofloxacin concentrations following a 
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Table 2. Urinary excretion of ciprofloxacin and fraction of the 
dose (%) excreted in aliquots in goats following a single 
intravenous injection of 4 mg/kg body weight (n = 4)
Time of Urine Fraction of the  % Recovery
sampling concentration total dose  of total
(h) (μg/ml) excreted (%) dose in urine 
0-3   402.50 ± 149.75 14.50 ± 3.64 14.50 ± 3.64
3-6 151.60 ± 28.14 10.60 ± 3.60 25.10 ± 7.24
6-9   37.35 ± 28.01   2.76 ± 2.02 27.86 ± 9.26
9-12 10.27 ± 5.25   0.88 ± 0.52 28.74 ± 9.78
12-24   2.36 ± 1.45   0.44 ± 0.22   29.18 ± 10.00
2 4-36   2.15 ± 2.31   0.26 ± 0.20   29.44 ± 10.20
36-48   1.57 ± 1.08   0.26 ± 0.14   29.70 ± 10.34
All data are mean ± SD.
Table 3. Efficacy predictors (C
0
p/MIC and AUC0-24/MIC) estimated for ciprofloxacin against Gram-negative and Gram-positive 
bacteria
Gram-negative bacteria Gram-positive bacteria
MIC = 0.015 (μg/ml) MIC = 0.06 (μg/ml) MIC = 0.25 (μg/ml) MIC = 0.5 (μg/ml) 
C
0
p/MIC 298.11 ± 56.49   74.53 ± 14.12 17.89 ± 3.39 17.89 ± 1.69
AUC0-24/MIC 744.44 ± 303.63 186.11 ± 75.91 44.67 ± 18.22 22.33 ± 9.11
For calculations the applied values were: C
0
p = 4.47 μg/ml. AUC0-24 = 11.16 μg.h/ml. This value is obtained after doubling the value of AUC0-12.
are presented in Fig. 1. The drug was detected in goat 
serum up to 12 h. Following intravenous administration, 
the elimination half-life (t1/2β), volume of distribution at 
steady state (Vdss), total body clearance (ClB), and area 
under curve from 0→∞ (AUC0→∞) were estimated to be 
1.63 ± 0.17 h, 2.012 ± 0.37 l/kg, 16.27 ± 1.87 ml/min/kg, 
and 5.75 ± 0.92 μg.h/ml, respectively (Table 1). The 
efficacy predictors, C
0
p/ minimum inhibitory concentration 
(MIC) and AUC0-24/MIC can predict antimicrobial 
efficacy of fluoroquinolones and to reduce selection for 
resistance [36]. Efficacy predictors for Gram-negative 
bacteria at MIC=0.06 μg/ml and gram-positive bacteria at 
MIC = 0.5 μg/ml were C
0
p/MIC = 74.53 ± 14.12, 
AUC0-24/MIC = 186.11 ± 75.91 and C
0
p/MIC = 17.89 ± 
1.69, AUC0-24/MIC = 22.33 ± 9.11, respectively (Table 3). 
  Ciprofloxacin concentrations in urine were much higher 
than in serum (Table 2, Fig. 1). Urinary recovery of 
ciprofloxacin was 29.70 ± 10.34% of the administered 
dose within 36 h post administration (Table 2). The in vitro 
protein percentage of ciprofloxacin at different concentration 
(0.5, 0.75, 1. 1.5, 2 μg/ml) was 20.5, 35.2, 49.3, 51.0, and 
49.0, respectively with the mean value 41.0 ± 13.1%. The 
in vitro protein binding of ciprofloxacin to serum protein 
was 41.0 ± 13.10%, and increased with increasing doses. 
Discussion
  Following intravenous administration of ciprofloxacin (4 
mg/kg), no adverse effect or toxic manifestation was 
observed. Ciprofloxacin concentration versus time data is 
best described by a biphasic curve and was similar to the 
disposition in pre-ruminant calves and piglets, goats, dogs, 
ponies, sheep, buffalo calves and cats [1,2,8,22,25,29,30]. 
The distribution of the ciprofloxacin appeared to be quite 
rapid, as indicated by short distribution half-life (0.108 ± 
0.03 h) and 2.11 fold reduction in the serum drug 
concentration within 30 min of its administration. The 
distribution half-life (t1/2α) in goats was similar to murrah 
buffalo calves [29]. However, the values were lower than 
the observed distribution half-life in pre-ruminant calves 
[25], cats [2], and cow calves [17]. 
  The elimination half-life was similar to that in rabbits [4] 
and goats [28]. Higher values were reported in cats [2], 
horses [26], cow calves [34], buffalo calves [30], and men 
[6]. Ciprofloxacin showed a Vdss (2.012 ± 0.37 l/kg) that 
indicates the drug is well distributed to extra-vascular tissue, 
as a volume of distribution of one indicates good extra-vascular 
tissue distribution [3]. This is supported by the high K12/K21 
ratio, which indicates that the drug moves freely between 
the body compartments, as reported in cats [2]. The Vdss 
values were similar in rabbits [9] and horses [26], but lower 
than in cats [2] and ponies [8]. Ciprofloxacin clearance in 
goats was similar to dogs [1], calves [25] and pigs [10]. 
This value in goats was higher than reported in men [6], 
buffalo calves [30], and cat [2] but lower than in lactating 
cow [15], and cow calves [34].
  Ciprofloxacin was detected in urine following intravenous 
administration, with a mean of 29.70% ± 10.34% of the 
total administered dose of ciprofloxacin recovered in urine 
within 36 h. Urine concentrations up to 36 h were above 
MIC90 for both Gram-positive and Gram-negative pathogens 
responsible for urinary tract infections, suggesting that 
ciprofloxacin could be used to treat goats with urinary tract 
infections caused by bacterial strains resistant to other 
commonly used antimicrobials. 244    R. Raina et al.
  Ciprofloxacin (0.5 to 2.0 μg/ml) protein binding averaged 
41.0%, comparable with Joos et al. [16] and Hoffken et al. 
[14] who reported serum binding between 21.9% and 
39.6% in human. 
    An optimum dosage is derived by correlating the 
important pharmacodynamic variables like in vitro MIC data 
with pharmacokinetic variables. The antibacterial activity of 
the fluoroquinolones is dependent on the drug concentration 
and the MIC of the micro-organisms [38]. Antimicrobial 
drugs that act predominantly by concentration-dependent 
mechanisms generally exert significant post-antibiotic, 
sub-minimum inhibitory concentration effects. Such drugs 
continue to inhibit bacterial growth for a period of hours 
after they have been completely removed from the system. 
Optimal outcomes with this type of bactericide require high 
concentrations, with therapeutic success correlating with 
the AUC/MIC ratio, while prevention of the development 
of resistance correlating with the C
o
p/MIC ratio [32]. 
Accordingly, the C
o
p/MIC90 and AUC24/MIC90 are the best 
parameters for predicting the antimicrobial effects of 
fluoroquinolones [21]. For fluoroquinolones, a C
o
p/MIC90 
higher than 3 produced 99% reduction in bacterial count, 
and a C
o
p/MIC90 of 8 or higher prevented the emergence of 
resistant organisms [7]. In addition, an AUC24/MIC90 
higher than 100 should give maximum clinical and 
bacteriology efficacy [36]. The numerical values of 
C
o
p/MIC90 and AUC24/MIC90 are substitute markers for 
predicting optimal dosage [35]. The AUC/MIC for cattle, 
sheep, goats, and camels were lower than 100-125 [19].
  Lower  and  upper  MIC90 values were used for the 
calculation of dosage regimen [39]. MIC90 values of 0.015 
and 0.06 μg/ml were used for Gram-negative bacteria (E. coli, 
Pasteurella spp., Salmonella spp., Klebsiella pneumonia, 
Proteus mirabilis, Bordetella bronchiseptica, and Haemophilus 
spp.). However, values for Gram-positive bacteria (Staphy-
lococcus aureus, Staphylococcus intermedius, Staphylococcus 
spp.) were 0.25 and 0.5 μg/ml [2]. MIC90 values of 0.007 
and 1 μg/ml were used for selected veterinary bacterial 
pathogens [27]. 
  The efficacy predictors, AUC0-24/MIC and C
0
p/MIC ratios 
(Table 3) are lower for Gram-negative than Gram-positive 
bacteria. However, for treatment of gram-positive bacteria 
with greater MIC, the predicted efficacy is lower. The 
minimum therapeutic concentration of fluoroquinolones is 
0.02-0.5 μg/ml [20]. Here, ciprofloxacin concentration in 
serum was MIC ＜ 1 μg/ml [28] up to 12 h, a level suitable 
for Gram-negative bacteria, and levels in urine up to 36 h 
were sufficient for treating both Gram-negative and 
Gram-positive microorganisms. Ciprofloxacin also shows 
post-antibiotic effects (PAE) that persist for 4 to 8 h. We 
therefore recommend once daily, intravenous ciprofloxacin 
at 4 mg/kg to maintain effective levels in serum or 36 h 
intervals for treating urinary tract infections in goats. 
    In conclusion, ciprofloxacin showed high efficacy 
predictors against Gram-negative bacteria with PAE. In 
addition, the high concentration of ciprofloxacin excreted 
in urine up to 36 h makes it a better therapeutic option for 
treating systemic infections, especially of Gram-negative 
bacterial origin, as well as acute urinary tract infections of 
resistant strains.
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